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ABSTRACT
Introduction: The new European Union (EU) Regulations on medical devices and on in vitro diagnostics 
provide manufacturers and Notified Bodies with new tools to improve pre-market and post-market 
clinical evidence generation especially for high-risk products but fail to indicate what type of clinical 
evidence is appropriate at each stage of the whole lifecycle of medical devices. In this paper we 
address: i) the appropriate level and timing of clinical evidence throughout the lifecycle of high-risk 
implantable medical devices; and ii) how the clinical evidence generation ecosystem could be adapted 
to optimize patient access.
Areas covered: The European regulatory and health technology assessment (HTA) contexts are 
reviewed, in relation to the lifecycle of high-risk medical devices and clinical evidence generation 
recommended by international network or endorsed by regulatory and HTA agencies in different 
jurisdictions.
Expert opinion: Four stages are relevant for clinical evidence generation: i) pre-clinical, pre-market; ii) 
clinical, pre-market; iii) diffusion, post-market; and iv) obsolescence & replacement, post-market. Each 
stage has its own evaluation needs and specific studies are recommended to generate the appropriate 
evidence. Effective lifecycle planning requires anticipation of what evidence will be needed at each 
stage.
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1. Introduction
It is generally accepted that appropriate clinical evidence must 
be generated to inform licensing, coverage, and reimbursement 
decisions for medical devices (MDs) in publicly funded health-
care systems. However, what constitutes ‘appropriate’ clinical 
evidence at each stage of the technology development process, 
in different jurisdictions and for different purposes, is still 
a matter of debate. Moreover, the application of the Medical 
Device Regulations 2017/745 [1] in 2021 and 2017/746 [2] and 
the proposal for a regulation of health technology assessment 
(HTA) [3] in the European Union, are further disrupting the 
regulatory and market access ecosystem for medical devices, 
especially for those for which clinical evidence is considered to 
be particularly important, such as the high-risk implantable med-
ical devices.
This paper summarizes the deliberations of an expert panel 
named ‘Evidence Council on Pathways to Clinical Evidence 
Generation for High-Risk Implantable Medical Devices.’ Our 
council, which included a selected group of experts from 
various jurisdictions and different backgrounds, including epi-
demiologists, health technology assessors, health economists, 
and policymakers, was created to debate the uncertainties and 
challenges concerning the generation of clinical evidence for 
devices across the product lifecycle. The final aim was to 
provide recommendations to all stakeholders engaged in gen-
erating and evaluating clinical evidence on high-risk medical 
devices.
The paper is structured as follows. First, the European 
regulatory and HTA contexts are presented in sections 1.1 
and 1.2 respectively, together with the implications of the 
upcoming new EU regulations for clinical evidence generation 
for medical MDs. These developments in the policy arena are 
considered essential background for our review. Section 1.3 
introduces the challenges of identifying the appropriate study 
designs throughout the product life cycle and section 2.0 
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clarifies the methods used to address these challenges. 
Section 3.0 illustrates the council’s recommendations by pro-
duct lifecycle stages and section 4.0 summarizes the key ele-
ments to reduce uncertainties by different stakeholders (e.g. 
manufacturers, regulators, and HTA bodies), in identifying the 
‘best fit’ study designs to generate the right clinical evidence 
to enable devices to progress smoothly through the whole 
product lifecycle.
1.1. EU regulation on medical devices
The Regulation (EU) 2017/745 on medical devices (MDR) and 
Regulation (EU) 2017/746 on in vitro diagnostic medical 
devices (IVDR) were officially published in May 2017, replacing 
the EU’s current Medical Device (MD) Directives (93/42/EEC, 
90/385/EEC and 98/79/EC). A transition time of three and 5 
years until May 26, 2020 and 2022 (for medical devices and 
in vitro diagnostics, respectively) was foreseen, to allow stake-
holders to meet the requirements of the respective MDRs. Due 
to the global Covid-19 pandemic, which is consuming almost 
all efforts and resources of the health systems, the date of 
application of the MDR 2017/745 has been recently deferred 
by 1 year, from May 2020 to May 2021 by Regulation 2020/ 
561 [4].
The new Regulations contain a series of extremely impor-
tant measures to modernize the current regulatory ecosystem 
for MDs in the EU, among which the following that have 
a direct bearing on evidence requirements:
i.stricter ex-ante control for high-risk devices via a new pre-market 
scrutiny mechanism with the involvement of a pool of experts at 
EU level; 
ii.the reinforcement of the rules on clinical evidence, including an 
EU-wide coordinated procedure for authorization of multi- centre 
clinical investigations; 
iii.the strengthening of post-market surveillance requirements for 
manufacturers; 
iv.improved coordination mechanisms between EU countries in the 
fields of vigilance and market surveillance. 
From a legal perspective, the replacement of Directives with 
Regulations aims at strengthening the harmonization of the 
regulatory process for medical devices at the EU level. In this 
way, the process of obtaining a CE mark in order to launch the 
product in the EU market will follow common and more 
transparent rules [5].
After obtaining a CE mark, medical device manufacturers 
may face subsequent ‘hurdles’ before their products can reach 
patients. In some EU countries, a product-specific HTA is 
required to support the pricing and reimbursement decisions 
for MDs. These decisions are made separately in various jur-
isdictions of the Member States (MS), with inevitable hetero-
geneity in the timing of decisions and in reimbursement 
coverage for the same product [6].
1.2. EU regulation on HTA
HTA conducted and reported in different countries are not 
fully generalizable across MS [7–10]. This is due to potential 
differences in patient populations and in clinical pathways and 
disease management, which contribute to differences in the 
availability of alternative treatments, and in the general set-
tings of the health care There are also differences among MS 
in how the clinical evidence is used in HTA. In some MS, the 
clinical evidence is used to give a judgment of the ‘added 
clinical value’ of the product, which may then be used in price 
negotiations [11]. In other MS, the available clinical evidence is 
synthesized with other forms of evidence in a decision-analytic 
model. Finally, the preferred form of clinical evidence for HTA 
in most situations is the comparative effectiveness between 
the new technology and the existing standard of care. This 
may or may not be the same as the clinical evidence used in 
the regulatory process [12–14].
However, product-specific HTA methodology and results 
available from other MS represent important benchmarks 
and guidance for national/local adaptations and conclusions, 
without unnecessary duplication of work – in line with the 
primary aims of transferability research [15].
Some form of collaboration between MS on HTA began about 
30 years ago. However, it became systematic and organized with 
the creation in 2006 of EUnetHTA, the network of European HTA 
agencies, which today has over 80 organizations from 30 different 
countries. More than 10 years after the launch of EUnetHTA, at the 
beginning of 2018 the European Commission released to the 
European Parliament and the Council, a proposal for a new HTA 
regulation [3], in order to improve the functioning of the EU 
internal market and to promote the health of EU patients. 
Ultimately, the regulation aims at replacing the current voluntary- 
based network ‘EUnetHTA’ into a permanent consortium of 
nationally authorized institutions, that are expected to incorporate 
Article highlights
● High-quality clinical evidence is required to protect patients’ health, 
to effectively inform regulatory, coverage, and reimbursement 
decisions.
● The new EU Regulation on medical devices aims at improving pre- 
market and post-market clinical evidence generation, but fails to 
indicate what type of clinical evidence is appropriate at each stage 
of the lifecycle of medical devices.
● HTA in EU Member States is not uniform with respect to clinical 
evidence requirements and is one of the reasons why the proposal of 
an EU HTA Regulation is still under discussion at the EU Council.
● Different approaches exist to inform clinical evidence generation 
across a technology’s life cycle but encourage linearity in product 
development, in a particular order, each requiring a particular type of 
clinical evidence; this does not often apply to medical devices.
● Some jurisdictions have progressed in terms of recommendations for 
new types of studies to generate clinical evidence in the pre- and 
post-market stages, but no comprehensive and systematic picture 
exists so far.
● Recommendations are proposed for: i) the appropriate level and 
timing of clinical evidence throughout the lifecycle of high-risk 
implantable medical devices; and ii) how the clinical evidence gen-
eration ecosystem could be adapted to optimize patient access.
● Four stages are relevant: i) pre-clinical, pre-market; ii) clinical, pre- 
market; iii) diffusion, post-market; and iv) obsolescence & replace-
ment, post-market and must be seen in a continuum: ideally, clinical 
evidence needs in the later lifecycle stages can be prepared for from 
the outset.
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centralized clinical assessments into their own national HTA sys-
tems. While the assessment on clinical dimensions is centralized, 
the final recommendation (appraisal) on the added value of the 
technologies, and on their reimbursement, remains with the MS.
Overall, by focusing on transparency, independence, effi-
ciency, and quality of shared reports, the proposal aims to 
support evidence-based market access processes for innova-
tive technologies in the EU. Although these principles are 
difficult to question, the proposal only received a lukewarm 
endorsement by various stakeholders and, in some cases, has 
been criticized, despite extensive public consultations con-
ducted before the publication [16]. Major challenges remain 
concerning the role and acceptability of evidence from rando-
mized and real-world data, the trade-off between internal and 
external validity requirements, and the obligation for MS to 
use the clinical assessment by the EU HTA coordination group 
for coverage and reimbursement decisions at local level. While 
avoiding duplication, a uniform clinical assessment also leads 
to debate. For example, some MS consider appropriate current 
care as the comparator relevant for a new technology; if this 
differs between MS, it makes it difficult, if not impossible, to 
produce a uniform assessment. Skepticism on the efficiency 
and effectiveness of the coordination EU HTA group by some 
stakeholders has hindered a smooth approval process of the 
regulation, which is still under discussion at the EU Council.
1.3. Lifecycle evidence generation for high-risk medical 
devices: overview of different approaches
A common way to consider the data needs for evaluating new 
technologies is to relate these to various states in the technol-
ogy’s life cycle. A basic product lifecycle for a technology 
includes research, development, production, clinical use and 
obsolescence. These stages can be expanded as needed to 
address a specific device design or manufacturing procedure, 
as well as device class, category, and classification. The main 
concern is to define the life-cycle in a way that best meets the 
objective of generating timely and appropriate clinical evi-
dence, as it tracks various products and versions of products 
through development, the marketplace, and discontinuation 
(i.e. the company must still support those products in the 
marketplace even though their selling cycles have ended).
Different approaches have been proposed, and in some 
cases endorsed, by regulatory bodies. This is the case, for 
instance, of the Total-Product-Life-Cycle (TPLC) by the US 
Food and Drug Administration (FDA) [17] that combines data 
from various Center for Devices and Radiological Health 
(CDRH) databases to present an integrated record of premar-
ket and post-market activity for MDs. The main disadvantage 
of the TPLC approach is that it encourages linearity on our 
thinking, in that it portrays a series of steps in product devel-
opment, in a particular order, each requiring a particular type 
of clinical evidence. This approach works fairly well as a model 
for pharmaceutical product development, but the develop-
ment of MDs is often more unpredictable. For example, it is 
possible for MDs to enter into regular clinical practice with 
relatively little clinical evidence, the evidence being predomi-
nantly gained through actual use of the device in clinical 
practice [18], as opposed to a research setting [19,20]. The 
adaptation of the IDEAL (Idea, Development, Exploration, 
Assessment, Long term study) framework to medical devices 
[21] is another attempt to inform a continuous evidence gen-
eration for devices although the proposal is awaiting empirical 
implementation and fuller consideration by regulatory and 
HTA bodies.
Another key aspect is to determine the appropriate study 
design required for the clinical evidence to be generated at each 
stage of the MD development cycle. The randomized-controlled 
study (RCT) is usually considered to be the study design giving the 
highest level of evidence for demonstrating the efficacy of a new 
health technology, compared with an alternative, typically current 
standard of care. However, intrinsic or organizational features of 
MD technologies may make it difficult to carry out a conventional 
RCT [22]. Moreover, the question of comparative efficacy is not 
always the one to be addressed at different stages of the lifecycle 
of an MD product. Alternatives to the standard RCT design have 
been proposed in order to minimize the impact of specific pro-
blems of MDs such as the timing of the assessment, small eligible 
patient population and recruitment, acceptability to patients or 
physicians, inability to blind clinicians and patients, choice of 
comparator group, and learning curve [23,24]. Real-world evi-
dence – such as registries – have gained relevance to assess 
MDs over the last years [25–27]. Moreover, Bayesian methods are 
becoming increasingly applied to combine existing real-world 
data with information from the ongoing trial [28]. These methods 
are particularly useful in situations where the number of subjects is 
small, although a common disadvantage is the risk of including 
erroneous prior information derived from non-randomized data.
2. Methods
A multidisciplinary group, the ‘Evidence Council on Pathways to 
Clinical Evidence Generation for High-Risk Implantable Medical 
Devices,’ was conceived, created, and led by the Center for 
Research on Health and Social Care Management (CERGAS) – 
SDA Bocconi School of Management (Full details of the com-
position of our council are given in Appendix 1). The council 
was assembled to address the following questions:
Q1: What is the appropriate level (in terms of type, quantity, 
quality) and timing of clinical evidence that is sufficient to satisfy 
value assessors and payers’ needs throughout the lifecycle of 
high-risk implantable medical devices?
Q2: How could the evidence generation ecosystem be adapted 
to optimize patient access, considering the risks for patients, health-
care providers, payers and technology developers?
The workshops used a combination of modified Delphi and 
face-to-face expert panel methods to reach a consensus on 
the two questions. The Delphi method entails a group of 
experts who anonymously reply to questionnaires and subse-
quently receive feedback in the form of a statistical represen-
tation of the ‘group response,’ after which the process is 
repeated. However, it does not result in the same level of 
interaction as a live discussion. A live discussion can some-
times produce a better consensus, as ideas and perceptions 
are introduced, analyzed, and reassessed.
For these reasons expert panels can be more effective. They 
are used when specialized input and opinion is required for an 
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evaluation. Generally, a variety of experts are engaged, with 
various fields of expertise, to debate and discuss various 
courses of action and to make recommendations. They can 
be useful at different stages of an evaluation but have to take 
place to live, which can pose logistical challenges if experts are 
busy or geographically widespread.
Therefore, we used a combination of these techniques. 
Experts were selected to reflect different jurisdictions 
(European countries and Canada) and different backgrounds 
(health economics, public health, medicine, healthcare manage-
ment) (see Appendix 1). Invitations were sent by e-mail and, once 
accepted, a briefing paper was sent to all participants, in pre-
paration for the first round that consisted of a workshop held on 
June 14th, 2019 in Milan at SDA Bocconi School of Management. 
Those who could not physically attend the meeting were remo-
tely interviewed in the following few days by OC and AT. Consent 
to record the interviews was obtained and the audio record was 
transcribed. A medical writer took notes of the meeting discus-
sion and, along with interview transcripts, prepared a detailed 
overview of the discussion. This summary was emailed to experts 
in preparation for the second round, which was conducted as 
a second workshop at SDA Bocconi on October 25th, 2019, where 
the key points from the first round were discussed and recom-
mendations agreed. A detailed report of the discussion was 
prepared by a second medical writer, summarized by RT, OC, 
AT, and MD in preparation of the manuscript that was finalized 
with the contribution of all experts.
The discussion and recommendations proposed by our Council 
are mainly intended to apply to a ‘standard’ high-risk implantable 
MD without any particular special circumstances. For instance, 
devices that are suitable for a ‘breakthrough’ designation [29] or 
‘fast-track’ appraisal, such as those deemed ‘life-saving’ in addition 
to ‘high-risk’ or devices that are eligible for ‘conditional approval’ 
may have different requirements and are likely to deviate from the 
recommendations described here. According to Article 2 in the EU 
Regulation [1], an ‘implantable device’ is any device, including 
those that are partially or wholly absorbed, intended to be partially 
or totally introduced into the human body, or to replace an 
epithelial surface or the surface of the eye, by clinical intervention 
and which is intended to remain in place after the procedure for at 
least 30 days. In Annex VIII Rule 8 of the MDR, it is clarified that 
implantable devices and long-term surgically invasive devices will 
generally be classified as class IIb or higher. More specifically, 
medical devices intended to be used in direct contact with the 
heart, the central circulatory system or the central nervous system, 
active, wholly or mainly absorbed, with biological effect or under-
going a chemical change in the body, intended to administer 
medicinal products, are classified as class III. Ancillary components 
such as screws, wedges, plates, and instruments are considered as 
class IIb whilst implantable devices and long-term surgically inva-
sive devices intended to be placed in the teeth are classified as 
class IIa.
3. Results
Q1: What is the appropriate level (in terms of type, quantity, 
quality) and timing of clinical evidence that is sufficient to 
satisfy value assessors and payers’ needs throughout the 
lifecycle of high-risk implantable medical devices?
The recommendations given below outline the best stan-
dard of evidence attainable and the characteristics of the data 
collection process, in order to support the device’s approval 
and access to the end-user. Considering a lifecycle approach 
to the identification of pathways to clinical evidence genera-
tion, four stages were envisaged as being relevant, including 
the i) pre-clinical, pre-market; in addition to the ii) clinical, pre- 
market; iii) diffusion, post-market; and iv) obsolescence & 
replacement, post-market.
As a general rule, effective lifecycle planning requires 
anticipation of what evidence will be needed at each stage; 
ideally, evidence needs in the later lifecycle stages can be 
prepared for from the outset.
3.1. Pre-clinical, pre-market evidence generation
In the early pre-market stage, pre-clinical research on high-risk 
implantable medical devices, tests on toxicology, and biocom-
patibility are normally required, as defined by European cur-
rent standards for MDs [30]. This phase is intended for design 
optimization, prototype development, and manufacturing 
engineering. A recent trend gaining attention in this respect 
is the use of in silico trials. At their core, in silico trials make 
use of computer modeling and simulation to inform product 
design and predict how a novel medical product would per-
form in a particular patient or in a specific clinical setting. The 
possibility to gain a deeper understanding of the intrinsic 
properties of the device, as well as of the interactions with 
environmental or physiological characteristics of patients, 
early in the development phase may contribute to improve 
research efficiency. The potential of in silico trials has been 
recently recognized by regulatory bodies such as the US FDA, 
which has advocated the use of such systems as an additional 
innovative research tool [31]. FDA has advised that modeling 
and simulation could be used to, for example: 1) predict 
clinical outcomes, 2) inform clinical trial designs, 3) support 
evidence of efficacy and potential effectiveness, 4) identify the 
most relevant patients to study, and 5) predict product safety. 
However, they require more verification and validation [32].
At this stage it is also important for the MD manufacturer to 
explicitly start the definition of the appropriate ‘business case,’ 
or ‘value proposition’ for the technology; that is, the clinical 
need for the device, where the device sits in the diagnostic 
and therapeutic pathway, what advantages (if any) it may offer 
over existing alternatives (if any), what are the challenges that 
the new device may face when translating into regular clinical 
practice [33]. The challenges may relate to clinicians’ attitudes 
toward the technology, or the organizational changes that 
may be needed to support its adoption. Based on the answers 
to these questions, it should be possible to make an early 
assessment of the likely evidence needs of regulators, payers, 
and product end-users. It may even be possible to undertake 
some ‘early modeling’ of potential clinical and cost- 
effectiveness [34,35]. These activities are often referred to as 
‘early HTA’ and provide a conceptual framework to support 
industry and investors’ decisions on investments, plus the 
design and management of the technology, regulatory, and 
reimbursement strategies [36]. Indeed, early HTA consists of 
a range of methods, typically based on evidence derived from 
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bench and animal tests, early clinical experience, and previous 
generations of the technology [37]. The objective is to inform 
industry and other stakeholders (such as hospitals, providers, 
and potential users of the technology) about the potential 
value of new medical products in development, including 
methods to quantify and manage uncertainty about their 
potential clinical and cost-effectiveness.
In a nutshell, the early pre-clinical, pre-market stage is 
relevant since it should aim at paving the way to future, 
more extensive and costly clinical evidence leading to the 
‘value proposition.’ The following types of studies characterize 
this phase:
● toxicology and biocompatibility tests (e.g. materials test-
ing, microbiological safety, animal studies);
● in silico trials;
● early HTA.
3.2. Clinical, pre-market clinical evidence generation
In the pre-market phase, clinical investigations may begin with 
an exploratory approach to answer specific questions that may 
condition the continuation or suspension of the product’s 
development program. Exploratory trials include a small num-
ber of patients and expose them to the investigational med-
ical device-based procedure. These trials are de facto first-in- 
man studies, but often lack a therapeutic or diagnostic goal 
and, by definition, cannot establish safety, tolerability, or 
efficacy.
At this stage, early feasibility clinical investigations may be 
a relevant tool. These are defined as clinical investigations of 
a device early in development, typically before the device 
design has been finalized for a specific indication [38]. They 
can be used to evaluate the device design concept with 
respect to initial clinical safety and device clinical performance 
or efficacy (if appropriate), as per its intended use in a small 
number of subjects. Such studies may be particularly impor-
tant when this information cannot practically be provided 
through additional nonclinical assessments, or appropriate 
nonclinical tests are unavailable. Information obtained during 
early feasibility clinical investigation can guide device modifi-
cations. FDA has launched a specific Early Feasibility Study 
program to gain useful clinical experience to provide insights 
for sponsors and FDA review teams into device proof of con-
cept, patient characteristics that may impact performance, 
operator technique refinements, device safety, necessary 
device modifications, and human factors [39]. However, it 
should be clarified that speed of approval should not be 
gained at the expenses of substantial evidence for safety and 
effectiveness for high-risk devices. A recent study demon-
strated higher recall rates for devices approved with priority 
review vs. standard review at FDA highlighting concerns about 
the inherent risks of these first-in-class devices [40].
Ideally, consecutive patients treated with the investiga-
tional device, often in a single-arm, single-or multicentre 
study, should be tracked with an indication of the character-
istics of the investigational product, organizational factors 
(such as training and the learning curve), and safety and 
performance outcomes.
Whilst evidence from single-arm studies may be enough to 
assess acceptability and preliminary safety in some jurisdic-
tions, comparative data (ideally against current standard care) 
is often needed in others (e.g. UK and Germany, in the phar-
maceutical sector) [41]. In any case, planning for comparative 
effectiveness evidence generation should be made at this 
stage [42] so as not to unduly delay the HTA and reimburse-
ment process at a later stage [33]. Some HTA bodies, such as 
NICE [43] (in England and Wales), AQuAS [44] (in Spain) and 
EUnetHTA [45] (in the EU), already have programmes offering 
early scientific advice, or joint advice from the regulator and 
various payers. Discussion with stakeholders, including 
patients’ associations, is fundamental in this and other stages 
of the clinical research and product development and may 
profoundly influence the study design [42].
When the technology is considered as a replacement for 
the current standard, an RCT should ideally be carried out. 
Randomized controlled trials are considered the gold standard 
for comparative effectiveness assessment. A well-conducted 
randomized clinical trial, with well-established and valid end-
points for efficacy and short-term safety, is the ideal pivotal 
investigation. As the evidence generated in an RCT will typi-
cally be used to inform regulatory bodies, payers, and clinical 
practice in multiple countries [42], a pragmatic approach is 
generally to be preferred, so as to make the results as general-
izable as possible. In generalizing the results of a randomized 
trial, the assumption is not really that the patient population 
studied is representative of all patients but rather that the 
treatment effects should be transferable across healthcare 
systems [46]. Healthcare systems differ widely between coun-
tries, and each country’s approval system moves at a different 
rate. Nevertheless, valid estimates of the absolute benefits and 
harms of a treatment can be obtained by applying reliable 
proportional effects, obtained from randomized evidence, to 
the baseline risks within a particular population.
Generally speaking, robust clinical data generated through 
high-quality studies are probably valuable across countries 
and would likely form the ‘minimal dataset’ of clinical evi-
dence widely applicable for the regulatory and market access 
across different jurisdictions [47]. More complex and innova-
tive variants of the simple two-group parallel RCT exist and 
include adaptive designs [48] which make use of data col-
lected during the progress of a clinical study to allow mod-
ifications to the ongoing trial, such as dropping an ineffective 
arm or capturing incremental innovation throughout the eva-
luation process.
Whilst the cost of a standard RCT may be too high, and 
even prohibitive, for many small and medium device manu-
facturers, the explosion of electronic health records (EHRs) and 
the extraordinary penetration of mobile technology are cur-
rently fostering the digital innovation paradigm in the clinical 
trial sector [49]. Solutions are available to address various 
challenges from the study design to trial operations, data 
management, and report writing with a significant overall 
reduction in costs. In this regard, the Big Data for Better 
Outcomes (BD4BO) program by the Innovative Medicine 
Initiative as well as the European Database for Medical 
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Devices (EUDAMED), to be launched simultaneously for both 
medical devices and in-vitro diagnostics together in May 2022, 
may be potentially interesting [50,p.4] and, although accep-
tance of EHRs by regulatory bodies and HTA agencies is not 
common yet [51], the trend is for an increased use of this 
source of evidence.
There are several situations where an RCT is simply not 
possible or appropriate. These include 1) in small patient 
population where it is not possible to recruit sufficient num-
bers to demonstrate a statistically significant advantage over 
control, 2) when ethical issues discourage the use of a control 
or comparator arm (e.g. total artificial heart implantation), 3) 
when only considerably long-term outcomes are of interest 
(although an open-label period following an RCT may over-
come this problem). In cases where an RCT is impossible, it 
would be necessary for the device manufacturer to justify why 
this is the case and to work collaboratively with the regulatory 
authorities, HTA agencies/units, clinicians’ and patients’ repre-
sentatives to define a suitable alternative. Comparative evi-
dence would still be needed in these cases [42,52,53], and this 
may be derived from conditional inclusion of the device in 
a pre-established disease registry, or comparison of single-arm 
study data on the investigational device with a proper defined 
control group taken from historical cohorts or from a well- 
designed patient registry [51].
Bias is, of course, a concern in observational studies, where 
it is likely that systematic differences in the distribution of 
patient characteristics between treatment groups will affect 
the treatment effect. Proper adjustment is therefore necessary, 
through the use of covariates in a statistical analysis. The bias 
would be aggravated if the time frames or context between 
the investigational study and registry do not reasonably coin-
cide [54]. All these cause concerns regarding the validity of 
study design and the interpretability of study results, and 
consequently the ability of regulatory decision-making may 
be compromised. In this regard, the EU MDR 2017/745 estab-
lishes that manufacturers of Class III and certain Class IIb 
devices can access EU-level expert panels at a much earlier 
stage in the product development process, to obtain advice in 
relation to clinical development strategy and the proposal for 
clinical investigations. The independent panel experts will be 
selected on the basis of their clinical, scientific, or technical 
expertise in the field and shall perform their tasks with impar-
tiality, independence, and objectivity, to provide an indepen-
dent opinion on high-risk devices to Notified Bodies before 
such devices are certified for EU market access. The experts 
will also be involved in other tasks such as contributing to the 
development of common specifications for clinical evaluation 
of device categories, guidance documents, or standards. The 
ultimate aim is to improve manufacturers’ product develop-
ment plans, in order to facilitate better clinical data generation 
to satisfy Notified Bodies’ conformity assessment process. 
A call for interest in serving on the panels was issued by the 
European Commission, addressed to a wide array of profes-
sionals (from all medical specialties but also from other back-
grounds such as artificial intelligence, computer science, 
health outcomes research, statistics, etc. with at least 5-years 
experience in the area of medical devices or in vitro diagnos-
tics) last September [55]. Following the call for interest, the EC 
clarified that eligible candidates who are not part of an expert 
panel yet may be included in a central list of available experts 
who may be used to appoint replacements, request advice, or 
find support for the expert panels as needed [56].
A separate consideration relates to devices claiming 
equivalence to a predicate device [1,57]. An RCT maybe not 
strictly necessary in this situation. However, with the EU MDR, 
criteria for equivalence are stricter and equivalence should be 
demonstrated based on proper scientific justification and 
through access to the data relating to the predicate device 
(e.g. access to patient data of the pivotal RCT of the predicate 
device). The Clinical Evaluation – Equivalence guide to notified 
bodies and manufacturers issued by the MDCG [58] further 
clarifies the necessary requirements to claim equivalence by 
different classes of devices as from the MDR (Annex XIV, 
Part A).
Finally, in some European countries (e.g. Belgium, France or 
the UK), HTA may be conducted [59]. This HTA does not 
control the entry of the MD into the market but may control 
its level of reimbursement. This could be direct, by determin-
ing the extent to which reimbursement to hospitals or other 
providers are given for the procedure in which the device is 
used, or indirectly, by providing information on clinical or cost- 
effectiveness evidence that may influence the price negotia-
tions between device manufacturers and hospitals.
As mentioned earlier, some HTA bodies review the existing 
clinical data and make an assessment of ‘added clinical value.’ 
Other HTA bodies synthesize the existing clinical data with 
other available data for use in decision-analytic models to 
assess the comparative (clinical) effectiveness or cost- 
effectiveness of the new technology with the current standard 
of care. These models may use observational data to extra-
polate from the clinical data gathered in clinical trials [60].
The early scientific advice, mentioned earlier, can be impor-
tant in these situations, since the clinical data needs of the 
HTA bodies may be different from those of the regulators [61]. 
The extent of differences in data needs is likely to vary on 
a case-by-case basis. However, it is possible to identify three 
dimensions along which these differences in data needs are 
likely to be. First, HTA bodies almost always require clinical 
effectiveness data comparing the new technology and the 
existing standard of care. Hence, the preference of HTA bodies 
for head-to-head clinical studies where possible, or indirect or 
mixed treatment comparisons in the absence of head-to-head 
studies [62,63]. As to the regulatory phase, the Medical Device 
Coordination Group (MDCG) explains that when the device is 
compared against the ‘state of art,’ this must be supported by 
recognized guidelines by scientific societies or educational 
bodies [64]. Although comparative effectiveness vs. standard 
of care is not as binding as for HTA purposes, it is notable that 
the EU MDR acknowledges this case (recital 49) thus making 
evidential requirements between the regulatory and HTA pro-
cesses more consistent. Secondly, HTA bodies require clinical 
data that relates, as far as possible, to ‘real world practice’ in 
their local setting. For example, the current standard of care 
should be one that reflects actual clinical practice in the set-
ting concerned, and the clinical data should, as far as is 
possible, reflect the results obtained from using the device in 
the same, or similar, setting. This distinction, between the 
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efficacy of interventions in the controlled environment of 
clinical studies and their effectiveness in the real world, is 
particularly important in the case of MDs, given the potential 
impact of the user ‘learning curve’ and other organizational 
characteristics. Finally, HTA bodies tend to prefer data reflect-
ing patient-relevant outcomes in the long term. Therefore, 
they tend not to favor surrogate outcomes or biomarkers, 
but prefer outcomes like survival and health-related quality 
of life [47,65].
These clinical data preferences imply that, even if some 
RCTs comparing the new technology with the current stan-
dard of care do exist, in the HTA they are likely to be 
supplemented with data from observational studies, since 
these often include elements of ‘real world data.’ Therefore, 
various HTA bodies have begun to specify their need for 
and their likely use of observational data [51,60,66] 
although it must be acknowledged that – compared to 
other initiatives such as the Cochrane Collaboration [67] – 
the use of real-world data in HTA was foreseen since its 
inception [68]. The other main implication of the expressed 
preference for clinical data by HTA bodies is that it is 
unlikely that all these data would be available at the time 
the new device enters the market. This suggests that, 
although an HTA may be possible pre-market, any assess-
ment will need to be refined by data collected after the 
new device is being used in regular clinical practice. Indeed, 
it has often been argued that, while for pharmaceuticals the 
emphasis on clinical data collection is pre-launch, the 
emphasis for MDs might be post-launch. The EU MDR, 
together with the guiding documents issued by the MDCG 
[53], makes an effort to change this attitude by i) strength-
ening the clinical evidence requirements, and ii) advising 
manufacturers to develop a clinical development plan indi-
cating progression since from exploratory investigations. 
The collection of data post-market is discussed in the fol-
lowing section.
In summary, the clinical, pre-market stage is central since it 
aims to generate the evidence that will determine the appro-
priate place for the device in the market. Clinical evidence 
generation may go through different, incremental steps as 
described in Figure 1.
3.3. Diffusion phase, post-market evidence generation
Once the medical device is on the market, the EU MDR (article 
2, recital 60; Annex XIV, Part B) requires a ‘systematic proce-
dure to proactively collect and review experience gained from 
devices […] on the market […] for the purpose of identifying 
[…] any necessary corrective or preventive actions’ and con-
siders the post-market clinical follow-up as a continuous 
Figure 1. Clinical evidence generation in the clinical, pre-market stage.
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process [69]. Post-market evidence generation can take several 
forms, but the most common approach is to establish 
a registry or another type of prospective observational study. 
Several factors specific to medical devices make registries 
appropriate as a research methodology for post-marketing 
surveillance, or for informing the payers’ ultimate decision 
on pricing and reimbursement [25–27]. These factors include: 
uncertainty about long-term outcomes in what are often per-
manent implants, incremental design variation within a class 
of products, the potential for clinically significant heterogene-
ity in outcomes across populations due to patient-, operator- 
and organizational-factors, or extension of indications to other 
target populations [70]. Typically, a registry will accompany 
the device to bridge evidence gaps across the medical device 
total product life cycle.
The International Medical Device Regulators Forum (IMDRF) 
defines a registry ‘as an organized system with a primary aim to 
increase the knowledge on medical devices, contributing to 
improve the quality of patient care that continuously collects 
relevant data, evaluates meaningful outcomes, and compre-
hensively covers the population defined by exposure to parti-
cular device(s) at a reasonably generalizable scale (e.g. 
international, national, regional, and health system)’ [71]. 
Common characteristics that stand out in this and other defini-
tions of registry are: observational, non-interventional, post- 
authorization, long-term objectives and follow-up, high patient 
coverage, naturalistic (or ‘real world’) data collection, in contrast 
to the carefully selected populations of clinical trials.
A properly designed and well-executed national or interna-
tional registry has the potential to play an important role in 
the decision-making concerning medical devices. The key 
points here are: (1) how closely a registry approximates to 
standard clinical practice (procedures that do not pose more 
than minimal additional risk or burden to the safety of the 
subjects) and thus capture real-world data and (2) how simply 
a registry can be organized and conducted to maximize parti-
cipation and to ensure sustainability over the long term (3).
The PRECIS-2 (Pragmatic-Explanatory Continuum Indicator 
Summary 2) has identified nine domains (i.e. Eligibility, 
Recruitment, Setting, Organization, Flexibility in delivery and 
adherence, Follow-up, Outcomes, Analysis) that should guide 
a common rigorous approach to the design of a clinical study, 
on a continuum of explanatory attitude (ideal situation) to 
more pragmatic attitude (usual care) [72]. Ideally, registry 
data would be reliable, complete, consistent, accurate, and 
contain all relevant patient-, device-, operator- and organiza-
tional information, including all key baseline covariates and 
clinical and patients’ reported outcomes at baseline and fol-
low-up points. Ensuring transparency in the design, collection, 
access, and reporting of the data in the registry is of funda-
mental importance. High-quality registries can also serve as 
a basis for registry-based RCT, an innovative and efficient 
study design that can be particularly useful to investigate 
when the evidence of clinical benefit vs. the standard of care 
is small [47].
Consent is an important and sensitive issue. The EU clinical 
trial regulation [73] allows for a simplified informed consent to 
be obtained in single-country, low-intervention cluster trials 
where groups rather than individuals are allocated to 
a treatment. In general, consent in registries, relies on the 
balance between respecting data privacy and their public 
policy role. Another ethical consideration is outside- 
instructions for use (IFU) deployment of devices, analogous 
to ‘off-label’ use for drugs. This aspect would in fact allow the 
study of the performance of an approved device for a new 
indication (‘indication creep’) and make the registry a useful 
source for the pre-market stage evaluation in other indica-
tions. However in the EU, according to the Art.5(1) of MDR, 
a medical device is placed on the market if used in accordance 
with its intended purpose, that is an off-label use of a medical 
device is to all effects a nonconform use and is therefore 
discouraged.
The breadth of variables to be included for a device evalua-
tion may discourage systematic and extensive establishment 
of medical device registries. However, such limitations could 
be mitigated through interoperability solutions that strategi-
cally link complementary registries and data sources, to pro-
duce networks for which the data composite could support 
robust device evaluation, by adjusting for confounding factors 
and taking into account differences in key variables across 
countries, that can influence the results for a specific variable 
in each country. This is the approach proposed by the Medical 
Device Registries Task Force (MDRTF) in the US through the 
strategically coordinated registries network (CRN) [74]. The 
newly introduced unique device identification (UDI) imple-
mentation introduced by the EU MDR is certainly instrumental 
to the uptake of this new approach.
Registries’ outcomes can be very relevant to payers who 
need to know how devices perform once diffused, in order to 
eventually decide whether coverage and reimbursement are 
to be confirmed. For example, to payers, information on sec-
ondary effects or impacts of devices would be very useful, as 
secondary effects, such as hospital re-admissions, affect the 
whole process of patient care, and impact directly on budgets.
In addition, when designing registries, it is important to 
anticipate the needs of payers in conducting HTAs. Registries 
are likely to be more useful to payers if they include several 
devices of the same type or group, so that comparative clinical 
data can be collected. The outcomes measured in registries 
should also include those of interest to patients and payers, 
such as use of key resources and, where possible, assessments 
of patients’ quality of life. It is also important to include informa-
tion on relevant covariates that can be used to adjust for known 
confounders in observational studies. Finally, it may be of inter-
est to payers to enroll patients from different countries and 
settings, in order to explore the generalizability of clinical out-
comes from one setting to another. Some payers have entered 
into various types of performance-based risk-sharing arrange-
ments, such as ‘coverage with evidence development’ with 
device manufacturers. For example, several such arrangements 
were agreed between the Ontario Ministry of Health and manu-
facturers between 2000 and 2010 [75]. These arrangements take 
various forms but have the common feature that the device is 
approved for payment on the condition that more data on its 
clinical and cost-effectiveness are gathered. In principle, these 
arrangements appear to be particularly useful for MDs, given that 
the clinical data are often sparse when the device enters the 
market and there is an interest in assessing the effectiveness of 
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the device in regular clinical practice. However, there are several 
challenges in designing and conducting these arrange-
ments [76].
In a nutshell, the clinical evidence needed in the diffusion, 
post-market stage, can be drawn from registries or other 
observational study designs. Registries must be reliable, accu-
rate, and complete, i.e. they must contain all:
● patient-, device-, operator and organizational data;
● key covariates, clinical and patients’ reported outcomes 
at baseline and follow-up;
● data of all other devices of the same type used in routine 
practice so to help support policymakers’ evaluation;
● interoperability solutions that link complementary regis-
tries and data sources (e.g. electronic health records) can 
reduce their complexity and costs.
Therefore, stronger coordination at the EU level to leverage 
existing registries on same devices, currently scattered across 
different Member States, would be highly beneficial and 
would also help analyzing whether actual differences in rou-
tine practices in EU countries are truly preventing the EU from 
having a more centralized HTA process.
3.4. Obsolescence & replacement phase, post-market 
clinical evidence generation
The lifecycle of medical devices is normally shorter than drugs 
as products are replaced by newer, improved ones [77], often 
marketed by the same manufacturer. However, it is frequently 
the case that end-users and healthcare organizations are slow 
to adapt, which means that older devices tend to coexist with 
newer and more effective ones. In the very late stages of the 
product life cycle (i.e. obsolescence and replacement) guide-
lines need to incorporate new clinical evidence as soon as 
more effective devices enter the market, in order to inform 
end-users about stopping the use of old devices. Real-world 
data collection is important for old devices, until they are 
replaced by more innovative ones, since it frequently happens 
that a full picture of devices’ performance, effectiveness, and 
adverse events is not clear except in the very long-run. If 
newer, more innovative devices’ effectiveness and cost- 
effectiveness have to be compared with routine practice, it 
becomes important to gather sufficient clinical evidence for 
the standard of care, so to minimize uncertainty on its effec-
tiveness, given that a certain degree of uncertainty would 
inevitably remain around the newer devices’ performance till 
they progress through the learning curve.
Registries and electronic health records (EHR) can be appro-
priate at this stage to generate clinical evidence for old 
devices. Additional recommendations for EHR-based research 
on top of principled application of existing research and 
reporting guidelines have been proposed to improve the 
quality of EHR-based observational studies [78]. The digital 
transformation would also help in this regard as well as the 
development of a unique device identifier (UDI) for each 
medical device as prescribed by the EU MDR [1] and the US 
FDA [79] and its integration into EHR.
Recommendations for clinical evidence generation across 
the lifecycle of high-risk implantable medical devices are 
shown in Figure 2.
Q2: How could the evidence generation ecosystem be 
adapted to optimize patient access, considering the risks 
for patients, healthcare providers, payers and technology 
developers?
Clinical evidence generation for medical devices has tradi-
tionally been weaker than for drugs. This has led, in some 
cases, to scandals and loss of confidence among end-users 
and patients. The new EU regulations (MDR 2017/745 and 746) 
will improve the entire regulatory process for medical devices 
[1] and in vitro diagnostics [2], including clinical evidence 
generation. The stricter coordination at EU level will reduce, 
and hopefully eliminate, uneven assessments from Notified 
Bodies and competent authorities [5]. The EU MDRs are 
a great opportunity to improve the quality of clinical evidence 
across the entire life cycle of medical devices and to adopt 
a more participative approach that includes all stakeholders’ 
perspectives.
Regulators, payers, HTA agencies, end-users and patients’ 
perspectives would need to be taken into consideration, along 
the entire life cycle, from prototype development until aban-
donment and replacement of medical devices in order to 
minimize the risk to fail to deliver the potential benefits they 
could otherwise offer [33]. In this regard, the establishment of 
EU-level expert panels, who would advise both manufacturers 
and Notified Bodies on, respectively, the best study design to 
initially test devices’ performance and efficacy and safety, and 
to assess manufacturers’ clinical file, is an important innova-
tion brought about by the MDR thus introducing a systematic 
‘early dialogue’ approach. But this is not sufficient. Patients, 
payers, providers, and HTA agencies also need to be included 
in all phases, to streamline the whole process of clinical data 
generation so as to guarantee that promising medical devices, 
(i.e. those with an added value for the patients, end-users or 
the healthcare system), can progress from one step to another.
Thus, the new EU regulations offer a great opportunity to 
introduce a more integrated approach to decision-making and 
evidence generation for MDs, along the lines of the MARS 
Excite programme [80] in Canada. This programme is volun-
tary, and manufacturers can opt-in or not, depending on their 
perception of the value of early dialogue. However, in Europe, 
given the diversity among MS in the sophistication of HTA, 
a more coordinated programme would be beneficial. Given 
the plethora of MDs, even within Classes IIb and III, a key 
feature of such an integrated approach would be to determine 
the level of assessment required in each case. For example, 
minor modifications to existing devices, or new devices that 
are very similar to devices already on the market, may not 
need the same level of clinical assessment as devices that 
incorporate a completely new technology as also recom-
mended by the MDR 2017/745 that has also introduced stric-
ter requirements on when equivalence can be used as the 
basis for approval of a new high-risk medical device [58]. In 
addition, HTA could be quite ‘light touch’ if the new device is 
also not likely to have a premium price over existing ones. 
Therefore, priority setting to determine the level of assess-
ments required will direct our efforts toward expedited 
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assessment for those new devices that have the potential to 
be clinically and cost-effective, to the benefit of patients and 
the health-care system more generally.
The issue of how best to deal with the assessment with ‘fast 
follower’ devices (i.e. those very similar to a device or devices 
already on the market) needs particular consideration. 
Drummond et al [81] suggest that, if a registry has been set 
up in order to gather more evidence on the original device of 
that type, similar new devices could be added to the registry. 
This approach would have the dual benefits of (a) sharing the 
burden and cost of evidence generation among all the man-
ufacturers, rather than it being borne by the first to market 
and (b) enabling us to assess whether the devices are truly 
equivalent clinically.
This process will not come at zero costs. Manufacturers 
need to improve their knowledge of how the healthcare sys-
tems work and what the needs of different stakeholders are. 
Resources allocated to clinical evidence generation need to be 
prioritized and this can represent a challenge for small and 
medium-size companies. In such cases, a co-funding model 
may be applicable. In some jurisdictions, such as France, clin-
ical development funding can be obtained from the State for 
MDs considered as ‘innovative’ (e.g. 50:50 funding for clinical 
trials) [82]. Similarly, conditional adoptions (e.g. coverage with 
evidence development schemes) are becoming common in 
many jurisdictions and do help the industry to introduce 
innovative devices even when effectiveness has not been 
fully assessed [76].
Payers are keen to be involved even in the pre-market 
stage and see benefits in horizon scanning at a central (e.g. 
EU) level to help plan for future costs. Questions from 
industry to payers should be framed in terms of collabora-
tion/co-developers/partners rather than regarding them as 
‘assessors’. For payers, the main value drivers for a new 
device are the cost offset, the overall survival (OS) gain, 
and the quality of life gain (e.g. QALY) as well as other 
effectiveness measures. The payer wants to see data rele-
vant to these variables that can be used to estimate the 
value. Although this estimation usually comes after regula-
tory approval, early data collection should anticipate payer’s 
needs [47].
Patients’ needs and expectations are to be considered at 
all stages of the evidence generation, since they are increas-
ingly taking charge of their own health thus co-creating 
value. A disruptive wave of patient engagement is shifting 
health systems from a traditionally paternalistic, provider- 
focused stance to a new healthcare model that integrates 
patient experiences and preferences at all stages of the 
healthcare chain from basic and preclinical research to reg-
ulatory, market access, post-marketing surveillance, and dis-
ease management.
Finally, as mentioned earlier, it would be desirable if HTA 
agencies could contribute to clinical evidence generation 
since the early phases, i.e. pre-market, pre-clinical; by advising 
manufacturers and regulators on what the ‘business case’ 
should address in order to plan in advance a successful 
value proposition (e.g. target population, place in the care 
pathway) [33]. This is already the case in some jurisdictions 
and would be more widespread if there was a more integrated 
approach as discussed above.
4. Conclusions
Empirical evidence suggests that there is significant difference 
in the criteria used to evaluate high-risk implantable medical 
devices compared with high-risk pharmaceutical treatments 
[83]. Many authors argue that the evaluation of complex 
Figure 2. Recommendations on lifecycle evidence generation for high-risk implantable medical devices.
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medical devices is more challenging owing to a less well- 
developed regulatory evidence base and potential incremen-
tal improvements in efficacy over time. These arguments 
underline the importance of adequate evidence generation 
throughout the lifecycle of medical devices.
This overview seeks to address the issue of evidence gen-
eration for high-risk medical devices in European context. The 
issue is particularly relevant for the current policy agenda in 
the EU with the new MDR to come into force and HTA regula-
tion under discussion. Our discussion also contributes to the 
scientific literature on the issue by uncovering the main chal-
lenges of evidence generation in different stages of lifecycle of 
medical devices and provides suggestions on how best to 
overcome these challenges.
5. Expert opinion
Recent safety scandals and the COVID-19 pandemic have 
emphasized the issue of evidence generation for access to 
market of medical devices (MDs). While healthcare profes-
sionals were calling for new in vitro diagnostics that could 
more rapidly detect positive cases and hospitals were des-
perately searching for more life-saving devices to equip 
their intensive care units, governments and regulatory 
bodies struggled to keep the right balance between 
patients’ and professionals’ needs to access the technolo-
gies as quickly as possible and the necessity to assess 
whether they were safe and effective.
Evidential requirements for MDs have been the subject of 
debate for many years and in several jurisdictions. The 
regulatory systems for MDs have traditionally been less 
demanding in terms of clinical evidence generation com-
pared with those for drugs and this is one of the reasons 
why MDs often gain market access with insufficient evi-
dence to safely protect patients and to inform health policy 
decisions, such as coverage and reimbursement [84]. 
Moreover, MDs’ performance can often only be fully 
assessed after their use has become routine clinical practice. 
Regulatory and HTA agencies, as well as scientific organiza-
tions and societies, are trying to improve the current state 
of art, either by explaining why medical devices must be 
treated differently from drugs or by providing recommenda-
tions on the types of evidence needed to access the market. 
One interesting stream of research is the one that considers 
clinical evidence generation across the entire lifecycle of 
MDs. This is what the new EU Regulations on MDs and 
vitro diagnostics embrace. Also, if the proposal for an EU 
HTA Regulation were to pass, the whole lifecycle of medical 
technologies would be covered by the European 
Commission and a complete and comprehensive vision of 
clinical evidence generation would be needed.
Although several advances have been made in some 
jurisdictions for the type of evidence required to evaluate 
medical devices along their development phases, these are 
scattered across the countries of the EU and no uniform 
vision exists. Lack of consistency across countries, especially 
between Members States in EU, could prevent the new 
Regulations from achieving their objectives and the 
MedTech industry from allocating R&D investments at the 
right time and in the right clinical studies.
The lifecycle of medical devices can be characterized in 
pre-clinical pre-market; clinical pre-market; diffusion, post- 
market; and obsolescence & replacement, post-market. 
However, each stage must be prodromic to the next, so 
that a long-term, strategic vision would govern the devel-
opment of clinical studies across the entire lifecycle. In 
other words, manufacturers must have a clear idea of the 
‘business case’ for their product from the very beginning 
and must clarify the value proposition, knowing that indica-
tions, target populations and the expected added value may 
change as long as the product’s evidence is developed. 
However, these efforts must not be on manufacturers’ 
shoulders alone. Regulatory bodies, HTA agencies, patients’ 
organizations, payers, end-users and providers, all can con-
tribute to improving clinical evidence generation for MDs, 
through participating in the development of designs for 
clinical studies at all stages. Early dialogue and engagement 
with all stakeholders are essential, especially if their involve-
ment makes them feel co-creators rather than stakeholders.
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